REGENTIS BIOMATERIALS recorded a $2.6 million net loss for the six months ended June 30, 2026, while holding $8.952 million in cash and cash equivalents. The company remains in development and clinical stages without revenue, and its going-concern basis reflects uncertainty over future losses and the timing of profitability.

Key Highlights

  • REGENTIS BIOMATERIALS had $8.952 million in cash and cash equivalents as of June 30, 2026.
  • Total shareholders’ Equity was $7.681 million as of June 30, 2026, alongside an accumulated Deficit of $58.394 million.
  • The company reported $9.350 million in total Assets and $1.669 million in total liabilities as of June 30, 2026.

REGENTIS BIOMATERIALS LTD. (AMEX: RGNT) (AMEX: RGNT) reported a $2.6 million net loss for the six months ended June 30, 2026. The clinical-stage company had $8.952 million in cash and cash equivalents at June 30, 2026, against $1.669 million in total liabilities. Its interim financial statements were prepared on a going-concern basis, while the timing of profitability remains uncertain. The company has not generated revenues.

Cash Position and Balance Sheet

Total assets stood at $9.350 million as of June 30, 2026. Current assets accounted for $9.286 million, including cash and cash equivalents of $8.952 million and other current assets of $334,000. Long-Term Assets totaled $64,000. That amount comprised $32,000 in operating Lease right-of-use assets and $32,000 in net property and equipment. Total liabilities were $1.669 million. Current liabilities represented $1.651 million, including $195,000 in trade accounts payable, $1.445 million in other Accounts Payable and $11,000 in the current Maturity of an operating lease liability. Long-term operating lease liabilities were $18,000. The Balance Sheet showed $7.681 million in total shareholders’ equity. Additional paid-in Capital was $66.075 million, while the accumulated deficit was $58.394 million.

Equity and Share Count

REGENTIS BIOMATERIALS had 22,500,000 authorized ordinary shares as of June 30, 2026. Issued and outstanding ordinary shares totaled 7,023,921. The company’s interim statements show ordinary shares with no par value. The statements also report additional paid-in capital of $66.075 million and total shareholders’ equity of $7.681 million. The company’s financial condition includes an accumulated deficit of $58.394 million. Its financial statements use a going-concern basis while REGENTIS BIOMATERIALS continues its development and clinical activities.

Development-Stage Outlook

Management expects operating losses to continue from product development, clinical trials, regulatory activities and general administration. REGENTIS BIOMATERIALS said the extent of future operating losses and the point at which it becomes profitable are uncertain.